| melanoma

Imlygic vs Yervoy

Side-by-side clinical, coverage, and cost comparison for melanoma.

Deep comparison between: Imlygic vs Yervoy with Prescriber.AI

AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.

Safety signalsYervoy has a higher rate of injection site reactions vs Imlygic based on FDA-approved prescribing information

Coverage gaps3 major payers require step therapy for Yervoy but not Imlygic, including UnitedHealthcare

Category

Imlygic

Yervoy

At A Glance

RouteIntralesional injection

FrequencyEvery 2-3 weeks

ClassOncolytic viral therapy

RouteIV infusion

FrequencyEvery 3 weeks (monotherapy) or every 6 weeks (combination)

ClassCTLA-4 antagonist

Indications

Melanoma

melanoma
Renal Cell Carcinoma
Colorectal Carcinoma
Liver carcinoma
Non-Small Cell Lung Carcinoma
Malignant Pleural Mesothelioma
Squamous cell carcinoma of esophagus

Dosing

Melanoma Initial dose up to 4 mL at 1 million PFU/mL intralesionally; second dose 3 weeks later up to 4 mL at 100 million PFU/mL; all subsequent doses every 2 weeks up to 4 mL at 100 million PFU/mL.

Melanoma (unresectable or metastatic) 3 mg/kg IV every 3 weeks for 4 doses, or 3 mg/kg IV with nivolumab 1 mg/kg IV every 3 weeks for 4 doses followed by nivolumab monotherapy

Melanoma (adjuvant) 3 mg/kg IV every 3 weeks for 4 doses, then 3 mg/kg every 12 weeks for up to 4 additional doses

Renal Cell Carcinoma 1 mg/kg IV with nivolumab 3 mg/kg IV every 3 weeks for 4 doses, followed by nivolumab monotherapy

Colorectal Carcinoma 1 mg/kg IV with nivolumab 240 mg or 3 mg/kg IV (weight-based) every 3 weeks for 4 doses, followed by nivolumab monotherapy

Liver carcinoma 3 mg/kg IV with nivolumab 1 mg/kg IV every 3 weeks for up to 4 doses, followed by nivolumab monotherapy

Non-Small Cell Lung Carcinoma 1 mg/kg IV every 6 weeks with nivolumab 360 mg every 3 weeks, or with nivolumab and 2 cycles of platinum-doublet chemotherapy

Malignant Pleural Mesothelioma 1 mg/kg IV every 6 weeks with nivolumab 360 mg every 3 weeks

Squamous cell carcinoma of esophagus 1 mg/kg IV every 6 weeks with nivolumab 3 mg/kg every 2 weeks or 360 mg every 3 weeks

Contraindications

Immunocompromised patients, including those with primary or acquired immunodeficiency, leukemia, lymphoma, AIDS or other clinical manifestations of HIV infection, or on immunosuppressive therapy
Pregnant patients

—

Drug Interactions

26View drug interactions

677View drug interactions

Adverse Reactions

Most common (>=25%) Fatigue, chills, pyrexia, nausea, influenza-like illness, injection site pain

Serious Cellulitis (most common grade 3+ reaction), herpetic infection, injection site complications

Postmarketing Disseminated herpetic infections, including serious and fatal cases in immunocompromised patients

Most common (>=20%) fatigue, diarrhea, rash, pruritus, nausea, pyrexia, musculoskeletal pain, decreased appetite, cough, headache, dyspnea, vomiting, abdominal pain, arthralgia

Serious immune-mediated colitis, hepatitis, pneumonitis, endocrinopathies, nephritis, dermatologic reactions, neurological toxicities, myocarditis, adrenal insufficiency, hypophysitis, hyperthyroidism, hypothyroidism

Pharmacology

Oncolytic viral therapy; genetically modified live attenuated HSV-1 that replicates within tumors causing lysis and release of tumor-derived antigens, and produces GM-CSF to promote an antitumor immune response; exact mechanism of action is unknown.

Ipilimumab blocks CTLA-4, a negative regulator of T-cell activity, thereby augmenting T-cell activation and proliferation including tumor-infiltrating T-effector cells and reducing T-regulatory cell function.

View Full FDA Information

View full FDA information

Enter your patient's insuranceCheck specific coverage details for your patient.

Most Common Insurance

Anthem BCBS

Imlygic